OPHLY News and Press, Ono Pharmaceutical Co Ltd ADR

2024-05-22 13:50:44 ET More on Deciphera Pharmaceuticals Diving Into Deciphera Pharmaceuticals ONO to acquire Deciphera Pharmaceuticals in $2.4B deal Deciphera stock soars after Ono Pharmaceutical’s $2.4B buyout deal Seeking Alpha’s Quant Rating...

2024-05-11 21:00:08 ET Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 2024 Earnings Conference Call May 09, 2024, 08:30 PM ET Company Participants Gyo Sagara - Representative, Director, Chairman of the Board and CEO Tatsuya Okamoto - Corporate Officer, Executive Director of...

2024-04-30 08:07:36 ET More on Ono Pharmaceutical Co., Ltd. Historical earnings data for Ono Pharmaceutical Co., Ltd. Financial information for Ono Pharmaceutical Co., Ltd. Read the full article on Seeking Alpha For further details see: ONO to acquire Dec...

ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals PR Newswire OSAKA, Japan , April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Saga...

2024-01-23 17:10:35 ET Summary Merus N.V. shares have remained strong despite negative safety news about its MCLA-129 program, as attention shifts to promising candidates petosemtamab and zenocutuzumab. Petosemtamab shows solid overall response rates for head and neck cancer, whil...

Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million PR Newswire - Double the investment scale to accelerate open innovation and make strategic investments in bio-venture companies - OSAKA, Japan , Dec. 1, 2023 /PRNewswire/ -- O...

2023-08-31 06:45:33 ET More on Twist Twist Bioscience: Progress Hidden By Execution Issues And Soft Demand Twist Bioscience: Evaluating Its Conglomerate Of Innovation, Growth, And Vulnerabilities Twist Bioscience Corporation ( TWST ) Q3 2023 Earnings Call Trans...

2023-08-16 09:05:49 ET Summary Fate Therapeutics is a cell therapy company focused on CAR-T and NK cells for autoimmune diseases and cancer. Their product candidates are still in early clinical trials or preclinical stages, making their path forward uncertain. The company has ...

2023-05-23 13:40:20 ET Summary Shares of off-the-shelf cell therapy concern Fate Therapeutics, Inc. have cratered 95% since reaching an all-time high in January 2021, punctuated by the termination of its Johnson & Johnson deal. The company has essentially hit the reset button,...

Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...